Craneware’s 340B revenue slips in the final weeks of its financial year have pushed the AIM-listed healthcare software group’s full-year guidance below market expectations, sending shares down 20%. The company now forecasts FY26 revenue of $205–208 million and adjusted EBITDA of $65–67 million, both broadly flat on the prior year.
What drove the FY26 shortfall
The miss was concentrated in the second half of the year. Craneware’s H1 FY26 interim results (to December 2025) showed revenue of $105.7 million, up 6%, with adjusted EBITDA of $33.4 million, up 10%, and Annual Recurring Revenue (ARR) of $184.2 million, up 4%. Adjusted basic EPS reached 58.7 cents for the half, a 16% increase on the prior period.
The deterioration came late. According to the Craneware FY26 trading update, the company recognises a significant proportion of its 340B revenue when the customer actually receives the benefit from eligible drug purchases, not when the opportunity is first identified. That policy amplified the impact of a sharp slowdown in conversions during the final weeks of the year.
Craneware has identified around $500 million of outstanding qualifying drug purchases for hospital customers. The pace at which those opportunities converted into sales slowed sharply as pharmaceutical manufacturers expanded restrictions on the supply of 340B-priced medicines. A small number of large enterprise contracts also slipped into FY27.
Craneware 340B revenue and the manufacturer restriction problem
The Commonwealth Fund notes the 340B Drug Pricing Program, enacted in 1992, requires manufacturers to offer significant discounts on outpatient drugs purchased by federally designated safety-net hospitals and clinics. Those discounts underpin the revenue Craneware helps its hospital clients capture.
Manufacturer restrictions on access to those discounts have continued to tighten. The Cencora 340B manufacturer updates tracker shows AbbVie issued a notice effective 10 June 2026 changing its contract pharmacy policy with additional state-level exemptions, illustrating the ongoing expansion of restrictions in the final weeks of Craneware’s financial year.
The contract pharmacy channel is substantial. According to Drug Channels, as of 1 June 2025 approximately 32,000 pharmacy locations, close to 60% of the entire US pharmacy industry, operated as contract pharmacies for 340B participants. That market is increasingly concentrated among five large for-profit chains and pharmacy benefit managers: Cigna (via Express Scripts), CVS Health, UnitedHealth Group (via Optum Rx), Walgreens, and Walmart.
The squeeze on manufacturer access therefore flows through a commercially concentrated channel, limiting the ability of hospital customers to capture the eligible drug-purchase benefits Craneware’s platform is built to optimise.
Context: a strong run ahead of the stumble
The FY26 warning contrasts with the momentum Craneware had built. Craneware’s FY25 final results, published 15 September 2025, showed statutory profit before tax up 52% to $24.0 million (FY24: $15.7 million). Adjusted basic EPS reached 116.1 cents, up 22.5% from 94.8 cents in FY24. Total bank debt fell to $27.7 million from $35.4 million the prior year.
That trajectory made the abruptness of the H2 slowdown harder for investors to absorb. The FY26 guidance of $65–67 million adjusted EBITDA implies the group generated roughly $32–34 million in the second half, against $33.4 million in H1 alone.
The board said it will provide a further update alongside the group’s full-year results, expected in September 2026. Until then, the key question for investors is whether the $500 million pipeline of qualifying drug purchases converts at a faster rate once manufacturer restriction activity stabilises, or continues to face headwinds into FY27.
